Lupus Science & Medicine

Article	Citations
Mezagitamab in systemic lupus erythematosus: clinical and mechanistic findings of CD38 inhibition in an autoimmune disease	184
Differences in reproductive health discussions in an urban Hispanic population with SLE: lessons from the field	51
Evaluation and randomised controlled trial of home urinalysis testing in patients with SLE at elevated risk for developing lupus nephritis: a study protocol	41
B lymphocytes in treatment-naive paediatric patients with lupus are epigenetically distinct from healthy children	40
Genetic load in incomplete lupus erythematosus	40
SLESIS-R: an improved score for prediction of serious infection in patients with systemic lupus erythematosus based on the RELESSER prospective cohort	39
Intermittent and Persistent Type 2 lupus: patient perspectives on two distinct patterns of Type 2 SLE symptoms	33
Autoantibody-based subgroups and longitudinal seroconversion in juvenile-onset systemic lupus erythematosus	33
Novel multiclass classification machine learning approach for the early-stage classification of systemic autoimmune rheumatic diseases	31
Safety, immunological effects and clinical response in a phase I trial of umbilical cord mesenchymal stromal cells in patients with treatment refractory SLE	30
Absence of renal remission portends poor long-term kidney outcome in lupus nephritis	30
High-dimensional analysis of T-cell profiling variations following belimumab treatment in systemic lupus erythematosus	28
Langerhans cells infiltration in lymph nodes of patients with systemic lupus erythematosus	27
Generation of evidence supporting the content validity of SF-36, FACIT-F, and LupusQoL, and novel patient-reported symptom items for use in patients with systemic lupus erythematosus (SLE) and SLE wit	25
Canadian workplace experiences of systemic lupus erythematosus (SLE)	25
VPS13C and STING expression in neuropsychiatric systemic lupus erythematosus: unveiling an unbreached territory	24
Quick Systemic Lupus Activity Questionnaire (Q-SLAQ): a simplified version of SLAQ for patient-reported disease activity	23
Therapy with direct oral anticoagulants for secondary prevention of thromboembolic events in the antiphospholipid syndrome: a systematic review and meta-analysis of randomised trials	22
Novel immunoprofiling method for diagnosing SLE and evaluating therapeutic response	21
A better self-efficacy is predictive of better health-related quality of life (HRQoL) in patients with systemic lupus erythematosus: data from the Almenara Lupus Cohort	20
Renal response status to predict long-term renal survival in patients with lupus nephritis: results from the Toronto Lupus Cohort	20
Add-on sirolimus for the treatment of mild or moderate systemic lupus erythematosus via T lymphocyte subsets balance	20
Retinal toxicity in a multinational inception cohort of patients with systemic lupus on hydroxychloroquine	20
Investigation of the performance of validated cardiovascular risk scores in a global (UK/US) cohort of young people with childhood-onset systemic lupus erythematosus	19
Clarifying misbeliefs about hydroxychloroquine (HCQ): developing the HCQ benefits versus harm decision aid (HCQ-SAFE) per low health literacy standards	19

B cell polygenic risk scores associate with anti-dsDNA antibodies and nephritis in systemic lupus erythematosus	19
A multianalyte assay panel with cell-bound complement activation products demonstrates clinical utility in systemic lupus erythematosus	18
Safety of procuring research tissue during a clinically indicated kidney biopsy from patients with lupus: data from the Accelerating Medicines Partnership RA/SLE Network	18
Myocardial infarctions, subtypes and coronary atherosclerosis in SLE: a case–control study	18
Racial differences in clinical trial perceptions among a large, predominantly Black cohort of people with systemic lupus erythematosus in the Southeastern USA	17
Large overlap in neutrophil transcriptome between lupus and COVID-19 with limited lupus-specific gene expression	17
Impaired regulatory function of granzyme B-producing B cells against T cell inflammatory responses in lupus mice	17
To treat or not to treat with immunosuppressive therapy: psychiatric disorders in patients with systemic lupus erythematosus	16
Clinical features of Guillain-Barré syndrome and chronic inflammatory demyelinating polyradiculoneuritis associated with SLE	16
Sirolimus versus tacrolimus for systemic lupus erythematosus treatment: results from a real-world CSTAR cohort study	16
Genotype-guided new approach for dose optimisation of hydroxychloroquine administration in Chinese patients with SLE	16
Metabolic profiles of cutaneous lupus have abnormalities in the nicotinamide adenine dinucleotide pathway	16
Rare and common single nucleotide variants in childhood-onset systemic lupus erythematosus	15
Evaluation of the Montreal Cognitive Assessment as a screening tool for cognitive dysfunction in SLE	15
Systematic review of the reporting of extrarenal manifestations in observational studies of Saudi patients with systemic lupus erythematosus	15
Neutrophil gelatinase-associated lipocalin (NGAL) in lupus nephritis and beyond	15
Autoimmune encephalitis associated with anti-LGI1 antibody: a potential cause of neuropsychiatric systemic lupus erythematosus	15
Autoantibodies associated with systemic sclerosis in three autoimmune diseases imprinted by type I interferon gene dysregulation: a comparison across SLE, primary Sjögren’s syndrome and systemic scler	15
Clinical and immunological differences between primary and autoimmune-associated neuromyelitis optica spectrum disorders: a retrospective study	14
Lupus nephritis randomised controlled trials: evidence gaps and under-represented groups	13
Cardiovascular risk management in antiphospholipid syndrome: trends over time and comparison with rheumatoid arthritis and diabetes mellitus	13
Canadian patient experiences of lupus nephritis: a qualitative analysis	13
Patient and healthcare team recommended medication adherence strategies for hydroxychloroquine: results of a qualitative study informing intervention development	13
Treatment trends of systemic lupus erythematosus from 2007 to 2023 in the USA	12
Meeting report: patient and caregiver recommendations for a mobile health application for paediatric systemic lupus erythematosus	12
Altered hippocampal connectivity dynamics predicts memory performance in neuropsychiatric lupus: a resting-state fMRI study using cross-recurrence quantification analysis	12
Unravelling the TCRβ repertoire: a key to unlocking the immunopathogenesis and precision medicine in SLE	12
Evaluation of the LFA-REAL clinician-reported outcome (ClinRO) and patient-reported outcome (PRO): prespecified analysis of the phase III ustekinumab trial in patients with SLE	12
Cardiovascular risk factors and complications in patients with systemic lupus erythematosus with and without nephritis: a systematic review and meta-analysis	12
Evaluation of the effects of pre-exposure treatment with hydroxychloroquine on the risk of COVID-19 infection and on the efficacy of anti-COVID-19 vaccination during lupus or Gougerot-Sjögren’s diseas	12
Discrepant anti-dsDNA testing between EliA andCrithidiain ANA negative samples: just a false positive?	12
Positive psychosocial factors may protect against perceived stress in people with systemic lupus erythematosus with and without trauma history	11
Improving patient pathways for systemic lupus erythematosus: a multistakeholder pathway optimisation study	11
Cutaneous lupus concerns from the patient perspective: a qualitative study	11
Enhancing lupus outcomes by means of biology beyond overt clinical features, exemplified in an in-depth investigation of the effects of circadian rhythm disruption	11
Elevated serum neurofilament light chain levels in patients with neuropsychiatric systemic lupus erythematosus: a cross-sectional study	11
Lupus spectrum ambiguity has long-term negative implications for patients	11
Nailfold capillary scleroderma pattern may be associated with disease damage in childhood-onset systemic lupus erythematosus: important lessons from longitudinal follow-up	11
Comparison of short interval and low dose (SILD) with high dose of cyclophosphamide in the susceptibility to infection in SLE: a multicentrereal-world study	11
HNF-1β alleviates podocyte injury in lupus nephritis by maintaining endoplasmic reticulum homeostasis	11
Levels of physical activity in a large international cohort of patients with systemic lupus erythematosus	11
Changes in the incidence and prevalence of systemic lupus erythematosus between 1990 and 2020: an observational study using the Clinical Practice Research Datalink (CPRD)	11
Vitamin D level in patients with systemic lupus erythematosus: its relationship to disease course and bone mineral density	10
Immune complex–driven neutrophil activation and BAFF release: a link to B cell responses in SLE	10
Microarray testing in patients with systemic lupus erythematosus identifies a high prevalence of CpG DNA-binding antibodies	10
Evaluating disease control following belimumab treatment in patients with SLE enrolled in the US OBSErve study	10
Predictors of treatment response in a lupus nephritis population: lessons from the Aspreva Lupus Management Study (ALMS) trial	10
Medium-term impact of the SARS-CoV-2 mRNA vaccine against disease activity in patients with systemic lupus erythematosus	10
Development and psychometric evaluation of a physician global assessment for type 2 systemic lupus erythematosus symptoms	10
Risks of mortality and severe coronavirus disease 19 (COVID-19) outcomes in patients with or without systemic lupus erythematosus	10

Evaluation of RNase therapy in systemic lupus erythematosus: a randomised phase 2a clinical trial of RSLV-132	10
Adverse pregnancy outcomes in women with systemic lupus erythematosus: can we improve predictions with machine learning?	10
Personalised therapy during preconception and gestation in SLE: usefulness of 6-mercaptopurine metabolite levelswith azathioprine	10
Mer-tyrosine kinase: a novel susceptibility gene for SLE related end-stage renal disease	9
Investigations intoSCAMP5,a candidate lupus risk gene expressed in plasmacytoid dendritic cells	9
Disease-modifying therapies in systemic lupus erythematosus for extrarenal manifestations	9
Prediction of mortality risk in critically ill patients with systemic lupus erythematosus: a machine learning approach using the MIMIC-IV database	9
Pregnancy outcomes in antiphospholipid antibody positive patients: prospective results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinica	9
Proteomics uncovers ICAM2 (CD102) as a novel serum biomarker of proliferative lupus nephritis	9
Assessing the validity of QRISK3 in predicting cardiovascular events in systemic lupus erythematosus	9
Topological structural characteristics in patients with systemic lupus erythematosus with and without neuropsychiatric symptoms	9
Curcumin attenuates lupus nephritis by inhibiting neutrophil migration via PI3K/AKT/NF-κB signalling pathway	9
Factors influencing therapeutic efficacy of denosumab against osteoporosis in systemic lupus erythematosus	9
Clinical outcome in patients with suspected inflammatory neuropsychiatric lupus treated with immunosuppression: an observational cohort study	9
Higher mortality risk from gynaecological neoplasms and non-Hodgkin’s lymphoma in patients with systemic lupus erythematosus: an observational study from the Spanish National Registry	9
Severe flares are associated with a poorer health-related quality of life (HRQoL) in patients with SLE: data from the Almenara Lupus Cohort	8
Association of COVID-19 pandemic-related concern and health routine changes with functioning among individuals with systemic lupus erythematosus	8
Identification and functional characterisation of a novel DNASE1L3 variant (c.572A>G, p.Asn191Ser) in three Emirati families with systemic lupus erythematosus and hypocomplementaemic urticarial vas	8
Anifrolumab in lupus nephritis: results from second-year extension of a randomised phase II trial	8
Impact of low-dose acetylsalicylic acid on pregnancy outcome in systemic lupus erythematosus: results from a multicentre study	8
Safety and efficacy of belimumab in older adults with SLE: results of an integrated analysis of clinical trial data	8
Relationship between retinal microvascular impairment and subclinical atherosclerosis in SLE	8
Protocol for virtual physical examination in an observational, longitudinal study evaluating virtual outcome measures in SLE	7
Comorbidity and healthcare utilisation in persons with incident systemic lupus erythematosus followed for 3 years after diagnosis: analysis of a claims data cohort	7
Remission of lupus nephritis: the trajectory of histological response in successfully treated patients	7
Real-world treatment patterns, healthcare resource utilisation and costs in patients with SLE in the USA	7
LLDAS (lupus low disease activity state) and/or remission are associated with less damage accrual in patients with systemic lupus erythematosus from a primarily Mestizo population: data from the Almen	7
Machine learning-based identification of novel hub genes associated with oxidative stress in lupus nephritis: implications for diagnosis and therapeutic targets	7
Real-world oral glucocorticoid use in SLE: a nation-wide population-based study using the French medico-administrative (SNDS) claim database	7
Predictors of increase in chronicity index and of kidney function impairment at repeat biopsy in lupus nephritis	7
Transcription factor Fli-1 impacts the expression of CXCL13 and regulates immune cell infiltration into the kidney in MRL/lpr mouse	7
SF-36v2 and FACIT-Fatigue quality of life improvements with organ-specific SELENA-SLEDAI response and belimumab treatment in patients with systemic lupus erythematosus	7
Social Factors, Epigenomics and Lupus in African American Women (SELA) Study: protocol for an observational mechanistic study examining the interplay of multiple individual and social factors on lupus	7
Prevalence of major adverse cardiovascular events among Saudi patients with systemic lupus erythematosus compared with the general population: updates from the national SLE and PURE cohorts	7
Learning from serum markers reflecting endothelial activation: longitudinal data in childhood-onset systemic lupus erythematosus	7
Assessment of cardiovascular risk tools as predictors of cardiovascular disease events in systemic lupus erythematosus	7
Systemic lupus in the era of machine learning medicine	7
Utility of the ACR-1997, SLICC-2012 and EULAR/ACR-2019 classification criteria for systemic lupus erythematosus: a single-centre retrospective study	7
Health information use by patients with systemic lupus erythematosus (SLE) pre and during the COVID-19 pandemic	7
Outcome clusters and their stability over 1 year in patients with SLE: self-reported and performance-based cognitive function, disease activity, mood and health-related quality of life	7
Infection hospitalisation in systemic lupus in Sweden	6
Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies	6
Smoking associates with increased BAFF and decreased interferon-γ levels in patients with systemic lupus erythematosus	6
COVID-19 prognosis in systemic lupus erythematosus compared with rheumatoid arthritis and spondyloarthritis: results from the CONTROL-19 Study by the Italian Society for Rheumatology	6
Therapeutic drug monitoring of mycophenolic acid and clinical outcomes of lupus nephritis: a systematic review and meta-analysis	6
Immunogenicity of the third and fourth BNT162b2 mRNA COVID-19 boosters and factors associated with immune response in patients with SLE and rheumatoid arthritis	6
Real-world treatment patterns in patients with systemic lupus erythematosus: associations with comorbidities and damage	6
Activation-induced colocalisation of SCAMP5 with IFNα in human plasmacytoid dendritic cells	6
Celastrol ameliorates lupus by promoting apoptosis of autoimmune T cells and preventing autoimmune response in MRL/lpr mice	6
Serum interferon-alpha predicts in-hospital mortality in patients hospitalised with acute severe lupus	6
Panoramic view of clinical features of lupus erythematosus: a cross-sectional multicentre study from China	6
Association of phenotypic frailty and hand grip strength with telomere length in SLE	6
Dialogue: Antiplatelet effects of hydroxychloroquine in patients with systemic lupus erythematosus evaluated by the total thrombus-formation analysis system (T-TAS)	6
Outcomes following immunosuppressive therapy withdrawal after complete renal response in proliferative lupus nephritis	5
Development of a predictive model for systemic lupus erythematosus incidence risk based on environmental exposure factors	5
Associations between circulating interferon and kynurenine/tryptophan pathway metabolites: support for a novel potential mechanism for cognitive dysfunction in SLE	5
State of current management of the heightened risk for atherosclerotic cardiovascular events in an established cohort of patients with lupus erythematosus	5
Myocardial Performance Index to assess cardiac function in autoimmune connective tissue disease: a systematic review and meta-analysis	5
Vaginal microbiota affects urinary tract infection risk in women with systemic lupus erythematosus: a pilot cross-sectional study from Thailand	5
Can conventional brain MRI support the attribution process in neuropsychiatric SLE? A multicentre retrospective study	5
Renal response at 2 years post biopsy to predict long-term renal survival in lupus nephritis: a retrospective analysis of the Hopkins Lupus Cohort	5
p16Ink4a, a marker of cellular senescence, is associated with renal disease in the B6.NZMSle1/Sle2/Sle3mouse model of lupus	5
Circulating extracellular vesicles in Systemic Lupus Erythematosus: physicochemical properties and phenotype	5
Development of a lupus nephritis suboptimal response prediction tool using renal histopathological and clinical laboratory variables at the time of diagnosis	5
Abnormally high expression of D1-like dopamine receptors on lupus CD4+T cells promotes Tfh cell differentiation	5
Postmarketing safety evaluation of belimumab: a pharmacovigilance analysis	5
Comparison of flares in 85 patients with SLE who maintained, discontinued or reduced dose of hydroxychloroquine during a prospective study of ophthalmological screening for retinopathy (PERFOCTAPS Stu	5
SARS-CoV-2 spike aggravates lupus nephritis and lung fibrosis in systemic lupus erythematosus	5
Inflammatory markers in saliva and urine reflect disease activity in patients with systemic lupus erythematosus	4
Case series of anifrolumab for treatment of cutaneous lupus erythematosus and lupus-related mucocutaneous manifestations in patients with SLE	4
5-Hydroxymethylcytosine in circulating cell-free DNA as a potential diagnostic biomarker for SLE	4
Association of genetic variation on X chromosome with systemic lupus erythematosus in both Thai and Chinese populations	4
Combining C reactive protein and serum albumin to predict 90-day mortality in systemic lupus erythematosus with serious community-acquired infections	4
Multidisciplinary re-evaluation of neuropsychiatric events to confirm the neuropsychiatric lupus diagnosis at an Indonesian tertiary hospital	4
Medication-related hospitalisations in patients with SLE	4
Changes in cardiorespiratory function and fatigue following 12 weeks of exercise training in women with systemic lupus erythematosus: a pilot study	4
Differential expression of IFN-α, IL-12 and BAFF on renal immune cells and its relevance to disease activity and treatment responsiveness in patients with proliferative lupus nephritis	4
Risk of psychiatric disorders and all-cause mortality with belimumab therapy in patients with systemic lupus erythematosus: a meta-analysis of randomised controlled trials	4
Using photovoice to investigate patient experiences of lupus nephritis in Canada	4
Efficacy of initial combination with belimumab in newly diagnosed childhood-onset lupus nephritis: a single-centre historical control study	4

Non-criteria antiphospholipid antibody profiles and thrombotic outcomes in a cohort of patients with systemic lupus erythematosus	4
Meeting report: the ALPHA project: a stakeholder meeting on lupus clinical trial outcome measures and the patient perspective	4
Pharmacokinetics of hydroxychloroquine in paediatric lupus: data from a novel, direct-to-family clinical trial	4
Intercurrent infection as a risk factor for disease flares in patients with systemic lupus erythematosus	4
Clinical significance of exostosin 1 in confirmed and suspected lupus membranous nephropathy	4
Frailty and emergency department utilisation in adults with systemic lupus erythematosus ≤65 years of age: an administrative claims data analysis of Medicaid beneficiaries	4
Comparison of TLR4, NF-κB and IRF3 expression in kidney tissue between lupus nephritis (LN) and systemic lupus erythematosus (SLE): a pristane-induced lupus mice model study	4
Selection of indicators reporting response rate in pharmaceutical trials for systemic lupus erythematosus: preference and relative sensitivity	4
Interleukin (IL) 16: a candidate urinary biomarker for proliferative lupus nephritis	4
Effect of hydroxychloroquine on pregnancy outcome in patients with SLE: a systematic review and meta-analysis	4
Real-world effectiveness of belimumab in patients with lupus in China: RELIABLE observational cohort study protocol	4
Correction: Differences in reproductive health discussions in an urban hispanic population with SLE: lessons from the field	4
Monoclonal gammopathy in systemic lupus erythematosus is associated with distinctive clinical course, malignancy and mortality rate: a single-centre retrospective cohort study	4
Comparison of a voclosporin-based triple immunosuppressive therapy to high-dose glucocorticoid-based immunosuppressive therapy: a propensity analysis of the AURA-LV and AURORA 1 studies and ALMS	4
Immune gene expression and functional networks in distinct lupus nephritis classes	4
Alignment of contraception use with the ACR reproductive health guidelines in women with systemic lupus erythematosus within the RISE registry	4
Time to onset of clinical response to anifrolumab in patients with SLE: pooled data from the phase III TULIP-1 and TULIP-2 trials	4
Rural–urban disparities in hospitalisation for myocardial infarction in systemic lupus erythematosus in the USA	4
2021 DORIS definition of remission in SLE: final recommendations from an international task force	3
Analysis of prognostic factors in diffuse large B-cell lymphoma associated with rheumatic diseases	3
Antibodies to FXa and thrombin in patients with SLE differentially regulate C3 and C5 cleavage	3
Depression, stigma and social isolation: the psychosocial trifecta of primary chronic cutaneous lupus erythematosus, a cross-sectional and path analysis	3
Type 1 interferon status in systemic lupus erythematosus: a longitudinal analysis	3
COVID-19 vaccination questionnaire in patients with systemic lupus erythematosus: an observational study	3
Membrane attack complex (MAC) deposition in renal tubules is associated with interstitial fibrosis and tubular atrophy: a pilot study	3
Red blood cell-derived phosphatidylserine positive extracellular vesicles are associated with past thrombotic events in patients with systemic erythematous lupus	3
Peripheral blood T-cell subset and its clinical significance in lupus nephritis patients	3
Effect of anti-P ribosomal and anti-NR2 antibodies on depression and cognitive processes in SLE: an integrated clinical and functional MRI study	3
Low versus high initial oral glucocorticoid dose for lupus nephritis: a pooled analysis of randomised controlled clinical trials	3
Association of patient copayment and medication adherence in systemic lupus erythematosus	3
Treatment patterns in paediatric and adult patients with SLE: a retrospective claims database study in the USA	3
Mortality patterns of SLE and the associated risk factors in Korean patients: a nationwide cohort study	3
Risk factors of flare in patients with systemic lupus erythematosus after glucocorticoids withdrawal. A systematic review and meta-analysis	3
Evaluation of SLE arthritis using frequency domain optical imaging	3
Low-dose belimumab for patients with systemic lupus erythematosus at low disease activity: protocol for a multicentre, randomised, double-blind, placebo-controlled clinical trial	3
Metabolomic analysis suggests thiamine monophosphate as a potential marker for mesenchymal stem cell transplantation outcomes in patients with SLE	3
Epidemiology of SLE in Italy: an observational study using a primary care database	3
Anti-KIF20B autoantibodies are associated with cranial neuropathy in systemic lupus erythematosus	3
Patients achieving low lupus disease activity state, systemic lupus erythematosus disease control or remission showed lower rates of organ damage during longitudinal follow-up: analysis of the Hopkins	3